Immune cell injection takes on Hard-to-Treat leukemia
NCT ID NCT06234904
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This early-stage trial tests an experimental cell therapy called IBR733 for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatment. The therapy involves giving immune cells by vein in repeated cycles. The main goals are to check safety, find the best dose, and see if the treatment can shrink or clear the leukemia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBR733 cell injection (immune cells given by IV)
What this could lead to
If safe and effective, this could point toward a new cell-based treatment option for people with hard-to-treat acute myeloid leukemia.
What could go wrong
This is an early, small Phase 1 trial focused on safety, not proof of cure. The treatment may cause side effects or fail to control the leukemia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- iCasp9 T Cells for Stem Cell Transplant Safety (NCT01494103)
- CASPALLO: Suicide Gene T Cells for Stem Cell Tra NCT00710892
- GvHD Prevention Trial with Cyclophosphamide, Bor NCT07675174
- LSD1 Inhibitor Iadademstat for AML Trial (NCT06357182)
- FT-2102 for IDH1-Mutated AML/MDS Trial (NCT02719574)
- Vedolizumab for GVHD Prevention Trial (NCT06815003)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••